Article Information
History
- September 25, 2020.
Copyright
The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Pamela C. Proud1,6,
- Daphne Tsitoura2,6,
- Robert J. Watson1,
- Brendon Y Chua3,
- Marilyn J. Aram1,
- Kevin R. Bewley1,
- Breeze E. Cavell1,
- Rebecca Cobb1,
- Stuart Dowall1,
- Susan A. Fotheringham1,
- Catherine M. K. Ho1,
- Vanessa Lucas1,
- Didier Ngabo1,
- Emma Rayner1,
- Kathryn A. Ryan1,
- Gillian S. Slack1,
- Stephen Thomas1,
- Nadina I. Wand1,
- Paul Yeates1,
- Christophe Demaison2,
- David C. Jackson3,
- Nathan W. Bartlett4,
- Francesca Mercuri2,7,# and
- Miles W. Carroll1,5,7,#
- 1National Infection Service, Public Health England (PHE), Porton Down, Salisbury, Wiltshire, United Kingdom SP4 0JG
- 2Ena Respiratory, Level 9, 31 Queen St, Melbourne, Victoria, 3000, Australia
- 3Department of Microbiology and Immunology, The University of Melbourne, at The Peter Doherty Institute for Infection and Immunity, 792 Elizabeth St, Melbourne, Victoria 3000, Australia
- 4Viral Immunology and Respiratory Disease group and Priority Research Centre for Healthy Lungs, University of Newcastle and Hunter Medical Research Institute, Newcastle, Australia
- 5Nuffield Dept of Medicine, Oxford University, Oxford, UK
- ↵#Correspondence to:
Professor Miles W. Carroll, National Infection Service, Public Health England (PHE), Porton Down, Salisbury, Wiltshire, United Kingdom SP4 0JG, Email: miles.carroll{at}phe.gov.uk, Telephone: 01980 612100, Dr Francesca Mercuri, Director of Operations, Ena Respiratory, Level 9, 31 Queen St, Melbourne, Victoria 3000, Australia, Email: fm{at}enarespiratory.com, Telephone: +61 411 403 241
↵6 These authors contributed equally
Posted September 25, 2020.
Prophylactic intranasal administration of a TLR2 agonist reduces upper respiratory tract viral shedding in a SARS-CoV-2 challenge ferret model
